8-K: Aethlon Medical Reports Fiscal Third Quarter 2024 Results and Highlights Oncology Trial Progress

Aethlon Medical announces financial results for Q3 2024, highlighting progress in oncology trials and cost-cutting measures.

Summary

• Aethlon Medical reported its financial results for the third fiscal quarter ended December 31, 2024.
• The company is focused on developing the Hemopurifier for cancer and life-threatening infectious diseases.
• Aethlon achieved a key milestone with the first patient treated in the Hemopurifier safety, feasibility, and dose-finding study for solid tumors.
• Patient enrollment is open at two Australian sites for the Hemopurifier cancer trial.
• Operating expenses decreased significantly by approximately 50% compared to the same quarter last year.
• The company had a cash balance of approximately $4.8 million as of December 31, 2024.
• Aethlon is actively responding to CDSCO's queries through the company's India CRO, Qualtran.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to progress in clinical trials and cost-cutting measures, but tempered by the risks associated with clinical development and regulatory hurdles.

Positives

• The first patient was treated in the Hemopurifier safety, feasibility, and dose-finding study for solid tumors.
• Two clinical sites in Australia are actively enrolling patients under the amended protocol.
• Aethlon received ethics committee approval from a site in India.
• Operating expenses decreased by approximately $1.8 million, or 50%, to $1.8 million for the quarter ended December 31, 2024, compared to $3.6 million for the quarter ended December 31, 2023.
• The company's net loss decreased to approximately $1.8 million in the fiscal quarter ended December 31, 2024, from approximately $3.5 million in the fiscal quarter ended December 31, 2023.
• Strategic cost-cutting measures have been implemented to optimize company resources.

Negatives

• Two patients were withdrawn from the Australian oncology trial due to outcomes related to their anti-PD-1 therapies.
• Regulatory changes in India have introduced additional documentation requirements, potentially delaying trial initiation.
• The company had a cash balance of approximately $4.8 million as of December 31, 2024.

Risks

• The company's ability to raise additional capital on terms favorable to the company, or at all, is a risk.
• Successfully completing development of the Hemopurifier is subject to risks and uncertainties.
• The company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting is not guaranteed.
• Unforeseen changes in regulatory requirements could impact the company's plans.
• The company's ability to cure deficiencies and continue to maintain its Nasdaq listing is a risk.

Future Outlook

The company anticipates continued enrollments in its Hemopurifier cancer trial as sites progress and believes the studies will help inform future oncology efficacy trials.

Management Comments

• We are pleased to report that the patient tolerated the procedure without complications, making a critical milestone for the safety, feasibility and dose-finding trials of the Hemopurifier in patients with solid tumors who have not responded to anti-PD-1 antibodies stated James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical.
• We currently have two clinical sites activated and open for enrollment in Australia, with a third site expected to be activated in February 2025.
• In addition, we have received ethics committee approval from a site in India.
• We also anticipate continued enrollments in our Hemopurifier cancer trial as these sites progress.
• While two previously recruited patients were withdrawn from the study due to outcomes related to their anti-PD-1 therapies, we believe that the recent protocol amendment will shorten trial timelines and support improved patient enrollment.
• As previously announced, we believe these studies will help inform future oncology efficacy trials.
• Furthermore, we have implemented strategic cost-cutting measures to optimize company resources, enabling us to maintain a strong focus on the high-impact oncology trials in both Australia and India.

Industry Context

Aethlon is targeting a significant unmet need in cancer treatment, as only approximately 30% of patients who receive pembrolizumab or nivolumab have lasting clinical responses, and the Hemopurifier aims to improve therapeutic response rates to anti-PD-1 antibodies.

Comparison to Industry Standards

• Aethlon's Hemopurifier is being developed to address the limitations of existing anti-PD-1 therapies like pembrolizumab (Keytruda) and nivolumab (Opdivo), which only show lasting clinical responses in approximately 30% of patients.
• Companies like Roche, Merck, and Bristol-Myers Squibb are major players in the immuno-oncology space with approved anti-PD-1/PD-L1 therapies.
• Aethlon's approach of removing extracellular vesicles (EVs) to enhance the efficacy of these therapies is a novel strategy compared to traditional drug development.
• The company's focus on safety, feasibility, and dose-finding trials is a standard approach in early-stage clinical development, similar to other biotech companies in the space.

Stakeholder Impact

• Shareholders: The progress in clinical trials and cost-cutting measures could positively impact shareholder value.
• Employees: Strategic cost-cutting measures may impact employees.
• Patients: Successful development of the Hemopurifier could provide a new treatment option for cancer patients.
• Clinical Sites: The protocol amendment aims to improve enrollment speed and reduce screen failures, benefiting clinical sites.

Next Steps

• Continue patient enrollment in Australian oncology trials under the amended protocol.
• Await approval from the regulatory agency CDSCO in India.
• Monitor developments related to Bird Flu, Marburg virus, and Ebola virus.
• Host a conference call to review financial results and corporate developments.

Key Dates